Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
72 hedge funds and large institutions have $266M invested in Orchard Therapeutics plc American Depositary Shares in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 26 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 26
11% less funds holding
Funds holding: 81 → 72 (-9)
32% less capital invested
Capital invested by funds: $392M → $266M (-$126M)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
75% less call options, than puts
Call options by funds: $63K | Put options by funds: $254K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$9.88M |
| 2 |
JP Morgan Chase
New York
|
+$5.59M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$4.17M |
| 4 |
CC
Casdin Capital
New York
|
+$1.14M |
| 5 |
Millennium Management
New York
|
+$739K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.41M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$6.89M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.17M |
| 4 |
Renaissance Technologies
New York
|
-$3.05M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.65M |
ORTX Hedge Fund Activity: Q3 2020 in Review
72 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q3 2020, worth a combined $266M — down 32% from $392M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ORTX and 9 opened new positions — a net loss of 8 holders — while 26 trimmed existing stakes and 24 added.
The largest buyer was RA Capital Management, adding an estimated $9.88M. The largest seller was T. Rowe Price Associates, cutting an estimated $9.41M.
- 72 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q3 2020, down from 81 in Q2 2020.
- Funds reported $266M of Orchard Therapeutics plc American Depositary Shares stock for Q3 2020, down 32% quarter-over-quarter.
- 9 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q3 2020 and 17 closed out, a net change of -8 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q3 2020 was RA Capital Management, an estimated $9.88M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q3 2020 was T. Rowe Price Associates, an estimated $9.41M sold.
Based on aggregated 13F filings for Q3 2020.